WSE:IGN

Stock Analysis Report

Executive Summary

Inno-Gene S.A. provides genetic diagnostic solutions in Poland.

Snowflake

Fundamentals

Adequate balance sheet and fair value.

Share Price & News

How has Inno-Gene's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

IGN

-0.03%

PL Life Sciences

0.02%

PL Market


1 Year Return

-34.2%

IGN

7.3%

PL Life Sciences

-3.3%

PL Market

Return vs Industry: IGN underperformed the Polish Life Sciences industry which returned 7.3% over the past year.

Return vs Market: IGN underperformed the Polish Market which returned -3.3% over the past year.


Shareholder returns

IGNIndustryMarket
7 Day0%-0.03%0.02%
30 Day-5.3%-3.2%-2.5%
90 Day13.8%-5.0%-7.4%
1 Year-34.2%-34.2%8.2%7.3%-0.4%-3.3%
3 Year-57.6%-57.6%63.6%55.4%11.3%3.4%
5 Year-33.1%-33.1%227.6%202.4%-1.0%-13.0%

Price Volatility Vs. Market

How volatile is Inno-Gene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inno-Gene undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: IGN (PLN2.14) is trading below our estimate of fair value (PLN16.18)

Significantly Undervalued: IGN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IGN is good value based on its PE Ratio (18.6x) compared to the Life Sciences industry average (39.7x).

PE vs Market: IGN is poor value based on its PE Ratio (18.6x) compared to the Polish market (10x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate IGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IGN is overvalued based on its PB Ratio (5x) compared to the XE Life Sciences industry average (3.5x).


Next Steps

Future Growth

How is Inno-Gene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

-4.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IGN's earnings are forecast to decline over the next 3 years (-4.9% per year).

Earnings vs Market: IGN's earnings are forecast to decline over the next 3 years (-4.9% per year).

High Growth Earnings: IGN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: Insufficient data to determine if IGN's revenue is forecast to grow faster than the Polish market.

High Growth Revenue: Insufficient data to determine if IGN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if IGN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Inno-Gene performed over the past 5 years?

4.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IGN has become profitable over the past 5 years, growing earnings by 4.4% per year.

Accelerating Growth: IGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IGN had negative earnings growth (-8.6%) over the past year, making it difficult to compare to the Life Sciences industry average (14%).


Return on Equity

High ROE: IGN's Return on Equity (19.9%) is considered low.


Return on Assets

ROA vs Industry: IGN's Return on Assets is below or equal to the Life Sciences industry average last year.


Return on Capital Employed

ROCE Improving: IGN's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Inno-Gene's financial position?


Financial Position Analysis

Short Term Liabilities: IGN's short term assets (PLN3.3M) do not cover its short term liabilities (PLN15.2M)

Long Term Liabilities: IGN's short term assets (3.3M) exceeds its long term liabilities (746.0K)


Debt to Equity History and Analysis

Debt Level: IGN's debt to equity ratio (24.2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if IGN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: IGN's debt is well covered by operating cash flow (362.9%).

Interest Coverage: IGN's interest payments on its debt are well covered by EBIT (9.9x coverage).


Balance Sheet

Inventory Level: IGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: IGN's debt is covered by short term assets (assets are 5.024360x debt).


Next Steps

Dividend

What is Inno-Gene's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.7%markettop25%7.4%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IGN's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

What is the CEO of Inno-Gene's salary, the management and board of directors tenure and is there insider trading?


CEO

Jacek Wojciechowicz 0

0yrs

Tenure

0

Mr. Jacek Wojciechowicz serves as President and R&D Director at Centrum Badan DNA Sp. z o.o. Mr. Wojciechowicz serves as the President of the Management Board at Inno-Gene S.A. 


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jacek Wojciechowicz

    President of the Management Board

    • Tenure: 0yrs
  • Kamil Malek

    Secretary & Member of the Supervisory Board

    • Tenure: 0yrs

Board Members

  • Jakub Sitarz

    Member of the Supervisory Board

    • Tenure: 0yrs
  • Rafal Sobczak

    Member of the Supervisory Board

    • Tenure: 0yrs
  • Andrzej Mackiewicz

    Vice Chairman of the Supervisory Board

    • Tenure: 0yrs
  • Kamil Malek

    Secretary & Member of the Supervisory Board

    • Tenure: 0yrs
  • Piotr Staniszewski

    Member of the Supervisory Board

    • Tenure: 0yrs
  • Krzysztof Królikowski

    Chairman of the Supervisory Board

    • Tenure: 0yrs

Company Information

Inno-Gene S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inno-Gene S.A.
  • Ticker: IGN
  • Exchange: WSE
  • Founded: 2006
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł12.200m
  • Shares outstanding: 5.70m
  • Website: https://www.inno-gene.pl

Location

  • Inno-Gene S.A.
  • Poznan Science and Technology Park
  • 46 Rubiez str.
  • Poznan
  • 61-612
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IGNWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNFeb 2011

Biography

Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It engages in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 21:25
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.